二甲双胍通过抑制成骨细胞RANKL生成减少甲状腺癌骨转移微环境中的肿瘤生长
研究探讨二甲双胍对甲状腺癌骨转移的治疗作用。体外和体内实验使用未分化甲状腺癌细胞系FRO和SW1736,并建立小鼠骨转移模型。结果显示二甲双胍减少癌细胞活力、延缓骨肿瘤生长、降低骨髓RANKL和破骨细胞数量,并阻断癌细胞条件培养基诱导的成骨细胞RANKL生成和破骨分化。67例甲状腺癌患者中骨转移者血清RANKL显著升高。作者认为二甲双胍在甲状腺癌骨转移中具有潜在治疗作用。
要点
- 二甲双胍在体外显著降低FRO和SW1736细胞活力,在体内减少SW1736骨肿瘤生长。
- 二甲双胍减少骨转移小鼠骨表面抗酒石酸酸性磷酸酶阳性破骨细胞数量并降低骨髓RANKL。
- 骨转移甲状腺癌患者血清RANKL水平显著高于仅肺转移或无远处转移患者。
核心结论
- 在骨转移微环境中,二甲双胍通过抑制癌细胞活力、阻断癌细胞诱导的成骨细胞RANKL生成及直接减少破骨细胞分化,有效减少未分化甲状腺癌肿瘤生长,提示其在该场景具有潜在治疗作用。
研究设计与样本
- 体外使用未分化甲状腺癌细胞系FRO和SW1736,体内建立胫骨内注射癌细胞的小鼠骨转移模型。
- 用FRO或SW1736条件培养基处理成骨细胞以模拟骨转移微环境。
- 招募甲状腺癌患者(伴或不伴骨转移)并检测血清RANKL水平,共67例。
主要发现
- 二甲双胍显著降低FRO和SW1736细胞体外活力,并减少SW1736体内肿瘤生长。
- 小鼠骨转移模型中,二甲双胍延缓骨内肿瘤生长,减少骨表面抗酒石酸酸性磷酸酶阳性破骨细胞数量,并降低骨髓RANKL。
- FRO或SW1736条件培养基显著增加成骨细胞RANKL生成并激活全骨髓培养中的破骨细胞分化,二甲双胍处理可阻断这些效应。
- 67例甲状腺癌患者中,骨转移患者血清RANKL水平显著高于仅肺转移或无远处转移患者。
- FRO或SW1736条件培养基中白细胞介素-6超家族刺激STAT3磷酸化,gp130阻断可抑制;二甲双胍通过AMPK磷酸化减少条件培养基诱导的STAT3磷酸化,并通过RANK/c-Fos/NFATC1信号抑制骨髓来源单核/巨噬细胞的破骨分化。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Metformin has antitumoral actions in human cancers, including the thyroid, while its effects on metastatic lesions are unclear. Patients with bone metastasis (BM) from thyroid cancers have poor survival. Because metformin inhibits the activation of osteoclasts, which has essential roles in BM, the aim of this study was to investigate the therapeutic effects of metformin on thyroid cancer BM and osteoclast activation in the bone microenvironment. Methods: The anaplastic thyroid cancer (ATC) cell lines FRO and SW1736 were used to test the antitumoral effect of metformin in vitro and in vivo. A murine model of BM was established by intratibial injection of cancer cells. To mimic the BM microenvironment, osteoblasts were treated with conditioned media from the FRO (FRO-CM) and SW1736 (SW1736-CM) cells. Thyroid cancer patients with or without BM were recruited, and the serum receptor activator of nuclear factor kappa-B ligand (RANKL) levels was measured. Results: Metformin treatment significantly reduced the viabilities of the FRO and SW1736 cells in vitro and the tumor growth of SW1736 in vivo. In the murine model of BM, metformin delayed tumor growth in the bone and decreased the numbers of tartrate-resistant acid phosphatase-positive osteoclasts on the bone surface with reduced RANKL in the bone marrow. Furthermore, FRO- or SW1736-CM significantly increased the osteoblastic RANKL productions and activated osteoclast differentiation in whole marrow cultures, which were blocked by metformin treatment. Among 67 thyroid cancer patients, the serum RANKL levels were significantly increased in BM patients compared with patients with lung-only metastasis or no distant metastasis. In addition, the interleukin-6 superfamily in the FRO- or SW1736-CM stimulated STAT3 phosphorylation, which was inhibited by gp130 blocking. Metformin treatment decreased the FRO- or SW1736-CM-induced STAT3 phosphorylation by AMPK phosphorylation. Metformin also inhibited the FRO- or SW1736-CM-induced osteoclastic differentiation of bone marrow-derived monocyte/macrophage by RANK/c-Fos/NFATC1 signaling. Conclusions: In the microenvironment of BM, metformin effectively reduced ATC tumor growth by inhibiting cancer cell viability, blocking cancer cell-induced osteoblastic RANKL production, which further activated osteoclastogenesis, and directly reduced osteoclast differentiation. These multifactorial actions of metformin suggest that it has potential therapeutic effects in thyroid cancer BM.
引用
- Shin HS, Sun HJ, Whang YM, et al. Metformin Reduces Thyroid Cancer Tumor Growth in the Metastatic Niche of Bone by Inhibiting Osteoblastic RANKL Productions. Thyroid. 2020. PMID: 32791889. doi:10.1089/thy.2019.0851
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。